Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19650075)

  • 1. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin.
    Katsetos CD; Dráberová E; Legido A; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):514-20. PubMed ID: 19650077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics.
    Katsetos CD; Draber P; Kavallaris M
    Anticancer Agents Med Chem; 2011 Oct; 11(8):719-28. PubMed ID: 21707498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class III beta-tubulin in human development and cancer.
    Katsetos CD; Herman MM; Mörk SJ
    Cell Motil Cytoskeleton; 2003 Jun; 55(2):77-96. PubMed ID: 12740870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
    Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
    Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines.
    Katsetos CD; Reddy G; Dráberová E; Smejkalová B; Del Valle L; Ashraf Q; Tadevosyan A; Yelin K; Maraziotis T; Mishra OP; Mörk S; Legido A; Nissanov J; Baas PW; de Chadarévian JP; Dráber P
    J Neuropathol Exp Neurol; 2006 May; 65(5):465-77. PubMed ID: 16772870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells.
    Katsetos CD; Dráberová E; Smejkalová B; Reddy G; Bertrand L; de Chadarévian JP; Legido A; Nissanov J; Baas PW; Dráber P
    Neurochem Res; 2007 Aug; 32(8):1387-98. PubMed ID: 17406983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?
    English DP; Roque DM; Santin AD
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):63-74. PubMed ID: 23259428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging microtubule targets in glioma therapy.
    Katsetos CD; Reginato MJ; Baas PW; D'Agostino L; Legido A; Tuszyn Ski JA; Dráberová E; Dráber P
    Semin Pediatr Neurol; 2015 Mar; 22(1):49-72. PubMed ID: 25976261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond grade: molecular pathology of malignant gliomas.
    Sulman EP; Guerrero M; Aldape K
    Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels.
    Pen A; Moreno MJ; Martin J; Stanimirovic DB
    Glia; 2007 Apr; 55(6):559-72. PubMed ID: 17266141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain tumor stem cells as research and treatment targets.
    Hide T; Takezaki T; Nakamura H; Kuratsu J; Kondo T
    Brain Tumor Pathol; 2008; 25(2):67-72. PubMed ID: 18987831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
    De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 15-Deoxi-Delta(12,14)-prostaglandin J2 is a tubulin-binding agent that destabilizes microtubules and induces mitotic arrest.
    Cocca C; Dorado J; Calvo E; López JA; Santos A; Perez-Castillo A
    Biochem Pharmacol; 2009 Nov; 78(10):1330-9. PubMed ID: 19576185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells.
    Bouchet BP; Puisieux A; Galmarini CM
    Eur J Cell Biol; 2011 Oct; 90(10):872-8. PubMed ID: 21820201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.